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Abstract
When purified under rigorous conditions, some murine anti-
double-stranded-DNA (anti-dsDNA) antibodies actually bind
chromatin rather than dsDNA. This suggests that they may
actually be antinucleosome antibodies that only appear to bind
dsDNA when they are incompletely dissociated from
nucleosomes. Experiments in murine models suggest that
antibody–nucleosome complexes may play a crucial role in the
pathogenesis of glomerulonephritis in systemic lupus
erythematosus. Some human monoclonal anti-DNA antibodies
are pathogenic when administered to mice with severe
combined immunodeficiency (SCID). Our objective was to
achieve stable expression of sequence-altered variants of one
such antibody, B3, in Chinese hamster ovary (CHO) cells.
Purified antibodies secreted by these cells were tested to
investigate whether B3 is actually an antinucleosome antibody.
The pathogenic effects of the antibodies were tested by
implanting CHO cells secreting them into SCID mice. Purified
B3 does not bind to dsDNA unless supernatant from cultured
cells is added, but does bind to nucleosomes. The strength of
binding to dsDNA and nucleosomes is dependent on the
sequence of the light chain. Mice that received CHO cells
secreting wild-type B3 developed more proteinuria and died
earlier than control mice that received nonsecreting CHO cells
or mice that received B3 with a single light chain mutation.
However, none of the mice had histological changes or
deposition of human immunoglobulin G in the kidneys.
Sequence changes may alter the pathogenicity of B3, but
further studies using different techniques are needed to
investigate this possibility.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune rheu-
matic disease of unknown aetiology, characterised by the
presence of autoantibodies against a multiplicity of nuclear,
cytoplasmic, and membrane antigens [1]. Autoantibodies that
bind double-stranded DNA (anti-dsDNA antibodies) are
present in approximately 70% of patients with SLE and are
believed to play a particularly important role in lupus nephritis.
These antibodies are practically specific to patients with SLE
[2] and there is a correlation between increased disease activ-
ity and raised levels of anti-dsDNA antibodies in many patients
[3,4]. Anti-dsDNA antibodies are found in the kidneys of
patients with lupus nephritis, but not with other types of
nephritis [5]. In mouse and rat models, several research
groups have shown independently that some murine or human
monoclonal anti-dsDNA antibodies can be deposited in the
kidneys, with associated glomerulonephritis and proteinuria
[6-11].R971
bp = base pairs; BSA = bovine serum albumin; CDR = complementarity-determining region; CHO = Chinese hamster ovary; dsDNA = double-
stranded DNA; EDTA = ethylenediaminetetraacetic acid; ELISA = enzyme-linked immunosorbent assay; FCS = fetal calf serum; H & E = haematoxylin 
and eosin; IgG = immunoglobulin G; MEM α = minimum essential medium, α modification; OD = optical density; PBS = phosphate-buffered saline; 
PBST = PBS/0.05% Tween20; SCID = severe combined immunodeficiency; SEC = sample-enzyme-conjugate; SLE = systemic lupus erythemato-
sus; ssDNA = single-stranded DNA.
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els that only a subset of circulating anti-DNA antibodies are
deposited in the kidney and are pathogenic. Both isotype and
binding properties distinguish pathogenic from nonpatho-
genic anti-dsDNA antibodies. Anti-dsDNA antibodies of the
immunoglobulin G (IgG) isotype are believed to be the major
culprits in the pathogenesis of lupus nephritis [4].
The precise binding properties of autoantibodies found in SLE
are likely to affect their pathogenicity. In particular, it is increas-
ingly recognised that some antibodies previously thought to
bind dsDNA are actually antichromatin antibodies [12]. In a
series of experiments, Berden and colleagues have shown that
nucleosome/antinucleosome complexes in mice can cause
glomerulonephritis by interacting with heparan sulphate in the
glomerular basement membrane [10,11].
In previous studies, we have investigated the pathogenicity of
a number of human antibodies, including the monoclonal
IgG1λ antibody B3, which was derived in our laboratory from
a patient with active SLE [13]. When hybridoma cells secret-
ing B3 were implanted into mice with severe combined immu-
nodeficiency (SCID), the antibody was shown to penetrate
cells and bind to their nuclei, both in the kidney and in other
organs [8]. The mice given B3 implants developed proteinuria,
although histological examination of their kidneys did not show
glomerulonephritis.
Sequence analysis of the heavy chain variable region (VH) and
light chain variable region (VL) of B3 [14,15] showed that it
possesses a number of features characteristic of IgG anti-
dsDNA antibodies reported from both mice [16] and humans
[17]. These include multiple somatic mutations and the pres-
ence of arginine residues at critical positions in the antigen-
binding site. A computer model of the three-dimensional struc-
ture of the B3–DNA complex suggests that binding is stabi-
lised by interaction of dsDNA with three arginines in B3, one
each in the complementarity-determining region 1 (CDR1) and
CDR2 of the light chain and another in CDR2 of the heavy
chain [18]. One of these arginines, at position 27a in CDR1
(R27a) of the B3 λ chain, has arisen by somatic mutation from
serine.
Expression and modification of murine and human anti-DNA
antibodies in vitro has shown that removal of arginine residues
often leads to a decrease in affinity for dsDNA [15,19-21]. We
have expressed variant forms of B3, in which particular
sequence alterations were introduced into the heavy or light
chains, transiently in COS-7 cells [15,22,23]. This method
was used to show that the pattern of somatic mutations in
B3Vλ is critical in determining its ability to bind dsDNA. In par-
ticular, reversion of R27a to serine (R27aS) in B3Vλ CDR1
resulted in a significant reduction in dsDNA binding, indicating
the importance of this arginine at the binding site [15,23].
When an extra arginine was introduced into CDR3 of the B3
light chain, by exchanging this CDR with that of another mon-
oclonal human anti-DNA antibody, 33H11 [23], the resulting
construct (designated B33Vλ) conferred increased ability to
bind dsDNA compared with either B3Vλ or 33H11Vλ.
These experiments, however, were all carried out using super-
natant from COS-7 cells. The supernatants were treated with
DNase, but this treatment is not sufficient to ensure that none
of the antibody is present in complexes with nucleosomes. It
was therefore possible that purified B3 might bind to nucleo-
somes or other chromatin derivatives but not to dsDNA.
Expression of variants of murine anti-DNA antibodies has
shown that sequence alterations that enhance binding to
dsDNA do not necessarily increase pathogenicity [20]. It was
therefore important for us to investigate whether the apparent
effect of the R27aS sequence alteration on the ability of B3 to
bind dsDNA was paralleled by an effect on pathogenicity. The
amount of whole IgG produced by transient expression in
COS-7 cells was too small to allow purification or for experi-
ments on pathogenicity in SCID mice to be carried out. It was
therefore necessary to establish a stable expression system
for production of recombinant B3 and its variants in Chinese
hamster ovary (CHO) cells.
Materials and methods
Assembly of 'supervectors' for expression
The 'expression supervectors' (containing both heavy chain
and light chain cDNA) were adapted from the single-chain
expression vectors that we previously used for our transient
expression experiments [15,22,23]. The original vectors
pG1D1 and pLN10 were both kindly given to us by Dr CA Ket-
tleborough and Dr T Jones at Aeres Biomedical, Mill Hill,
London.
Recombinant expression vectors – pG1D1 containing human
immunoglobulin B3VH cDNA, and pLN10 containing human
immunoglobulin VL cDNA – were constructed as described in
detail previously [15,22,23]. VH sequences were ligated into
pG1D1 as HindIII/BamHI fragments, distal to an immunoglob-
ulin leader sequence and proximal to a block of cDNA encod-
ing the Cγ1 constant region. The VH and Cγ1 sequences are
separated by an intron. Similarly, Vλ sequences were ligated
into pLN10 as HindIII/BamHI fragments, distal to an immu-
noglobulin leader sequence and separated by an intron from a
Cλ sequence that lies distal to the insert. In both pLN10 and
pG1D1, the inserted genes are expressed from a human
cytomegalovirus (hCMV) promoter (see Fig. 1).
Four different VL constructs were used: these were B3VL,
B3VL(R27aS), B33VL (which contains the sequence of B3VL
up to the beginning of framework region 2 and the sequence
of 33H11VL distal to that), and BUVL (which contains the
sequence of B3VL up to the beginning of framework region 2
and the sequence of UK-4VL distal to that). 33H11 is a human
monoclonal IgG anti-dsDNA antibody kindly given to us by
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UK-4 is a human monoclonal antiphospholipid antibody that
does not bind DNA.
To produce the supervectors, an EcoRI fragment containing
the promoter, the λ-constant-region gene, and the λ-variable-
region gene (of B3 wild type or variant) from the recombinant
plasmid vector pLN10 was ligated into the EcoRI linearised
vector pG1D1/B3VH. This cloning scheme is shown in Fig. 1.
The supervectors produced contain the genetic material nec-
essary to express a whole heavy chain and a whole light chain.
Stable expression of whole IgG molecules
Four different IgG-secreting lines were made. The first (desig-
nated line CHO-B3) contained cloned VH and VL sequences of
the human IgG antibody B3. The others contained B3VH with
the other three light chain constructs described above and
were designated CHO-B3(R27aS), CHO-B33, and CHO-BU,
respectively. The whole IgG molecules were expressed in
modified CHO cells (CHOdhfr-), kindly given to us by Mrs Ali-
son Levy (AERES Biomedical, Mill Hill, London, UK). This
CHOdhfr- cell line, DXB11, was used with kind permission
from its original developer, Prof Lawrence Chasin. One allele
of dhfr (a gene encoding dihydrofolate reductase) was deleted
in DXB11; the other allele carries a missense mutation result-
ing in a single amino acid substitution [24].
Using electroporation (1.9 kV, 25 µF), 10 µg of recombinant
supervector was transfected into 107 CHOdhfr- cells sus-
pended in 700 µl of PBS (pH 7.4). In each transfection exper-
iment, a negative control sample was prepared by
electroporation of the CHOdhfr- cells in the absence of plas-
mid DNA. The cells were incubated overnight in nonselective
growth medium (minimum essential medium, α modification
(MEMα)) containing ribonucleosides and deoxyribonucleo-
sides, 50 units/ml each of penicillin and streptomycin, and
10% ultralow-IgG FCS (all from Invitrogen, Paisley, UK)]. The
cells were then grown in selective growth medium (MEMα
medium without ribonucleosides and deoxyribonucleosides,
50 units/ml each of penicillin and streptomycin, and 10%
ultralow-IgG FCS). The supervectors contain a functional dihy-
drofolate reductase gene, dhfr, whereas the host CHO cells
do not. Consequently, only those cells that stably incorporate
the supervector will survive under these selective conditions.
After 10 to 14 days, foci of transfected cells were clearly visi-
ble. The foci were transferred into individual wells of a 24-well
tissue-culture plate containing selective growth medium and
allowed to grow until almost confluent, when the individual
wells were tested for antibody production using a whole-IgG
ELISA (see below). Those clones producing the highest levels
of antibody were selected for expansion in selective growth
medium. After expansion, these cells were submitted to meth-
otrexate amplification either with two successive rounds of
amplification at 10-9M and 10-7M methotrexate (CHO-B3 and
CHO-B3(R27aS)) or with a single round of amplification at 10-
8M methotrexate (CHO-B33 and CHO-BU).
Production of control, stable cell line for in vivo 
experiments
A control line that had undergone the same procedures and
stresses as the stable cell lines but that would not produce
Figure 1
Cloning method used to construct the supervectors by combining the light chain and heavy chain expression vectors
light chain and heavy chain expression vectors. (a) EcoRI restriction 
sites in recombinant light chain expression vector, pLN10, containing 
Vλ cloned DNA sequences. (b) EcoRI-digested light chain cassette 
containing human cytomegalovirus (HCMV) promoter, immunoglobulin 
leader sequence, light chain variable-region DNA sequence, and con-
stant-region DNA sequence. (c)Ligation of light chain cassette into 
EcoRI-linearised B3VH/pG1D1 heavy chain vector to produce the final 
supervector, containing all components required to produce whole 
IgG1. The four supervectors were constructed in the same way, using 
the appropriate EcoRI-digested light chain fragments leading to slight 
variations in the overall plasmid size. SV40, simian virus 40; V:C, varia-
ble : constant.
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CHOdhfr- cells with an expression vector that contained a
functional dhfr gene but no cloned VH cDNA or Vλ cDNA (the
'empty vector'). Consequently, these cells were not able to
express whole IgG. This control cell line was treated (i.e.
selected and amplified with methotrexate) exactly as the IgG-
producing cell lines were.
Assay of antibody production in supernatant of 
transfected CHOdhfr-cells
The stably transfected cells were grown to near confluence in
selective medium for 3 days and the supernatant was treated
with DNaseI (RNase-free), 7.5 units/ml of supernatant for 1
hour at 37°C, followed by the addition of ethylenediamine-
tetraacetic acid (EDTA) to a final concentration of 15 mM. The
supernatants were then assayed to determine the concentra-
tion of whole antibody. A viable cell count was carried out on
the cells in order to calculate the level of antibody production
in ng/106 cells per day. The whole-IgGλ-antibody ELISA was
as described in previous papers [15,22,23].
Affinity purification of antibody from CHO cells
The cells were transferred to Chemicon Europe Ltd (South-
ampton, UK) and grown in larger quantities using the selective
medium described above. Human IgG was purified from the
supernatant using a Protein A column and the product was
analysed for purity by SDS–PAGE and quantified by spectro-
photometry. Purified human IgG was sent back to our unit and
the amount of antibody was checked using whole-IgG ELISA
as described previously [15,22,23].
The affinity-purified antibodies were diluted in sample-enzyme-
conjugate (SEC) buffer (100 mM Tris HCl, pH7; 100 mM
NaCl; 0.02% Tween 20; 0.2%BSA) to a concentration of 50
µg/ml, then treated with 7.5 units/ml DNaseI at 37°C for 1
hour and then with EDTA, pH 8, to a final concentration of 15
mM to inactivate the enzyme. To investigate the effect of the
DNase step, ELISA tests were also carried out on antibody
diluted in SEC but not exposed to DNase.
To investigate the possible contribution of cofactors derived
from cell supernatant, the same ELISA tests were carried out
on antibodies diluted to a concentration of 50 µg/ml in super-
natant from COS-7 cells electroporated in the absence of
plasmid DNA. These supernatants contained no human IgG
(confirmed by ELISA). To investigate whether nucleosomes
could act as cofactors in the binding of these antibodies to
dsDNA, the same ELISA tests were carried out on antibody
diluted to a concentration of 50 µg/ml in SEC buffer contain-
ing nucleosomes at a range of concentrations from 1.5 µg
DNA/ml to 20 µg DNA/ml (nucleosomes were prepared and
quantified in terms of DNA content as described below).
Anti-DNA ELISA
Calf thymus DNA (Sigma, Poole, UK) was further purified by
phenol/chloroform extraction and sonicated to ensure repro-
ducible coating, single-stranded DNA (ssDNA) was removed
by passing the sample through a 0.45- µg Millex-HA filter (Mil-
lipore, Watford, UK), and concentration and purity were deter-
mined by spectrophotometer. This dsDNA was coated on
Nunc (VWR, Lutterworth, UK) Maxisorp plates and used in an
anti-DNA ELISA, as described previously [23]. Serum and
ascites samples from SCID mice were diluted 1:100 in PBS/
0.05% Tween20 (PBST) before being tested in this assay.
Antinucleosome ELISA
Nucleosomes were prepared from Jurkat cells, grown to con-
fluence. The cell membranes were disrupted with Dounce
buffer, which causes swelling of the cells, and a fine tissue
homogenizer that enables release of the nucleus without
destroying it. Nucleosomes were extracted by digestion with
micrococcal nuclease (final concentration 100 units/ml).
Digestion was terminated by adding EDTA to a concentration
of 2 mM followed by centrifugation at 600 × g for 5 min at 4°C.
Aliquots were then extracted in phenol and chloroform, puri-
fied in ethanol, and run on an agarose gel to check integrity by
confirming the characteristic oligonucleosome ladder pattern.
The concentration of dsDNA in the nucleosome sample was
approximately 1 mg/ml. This was derived by measuring the
optical density at 260 nm using a spectrophotometer. This
method for extraction and quantitation of nucleosomes is sim-
ilar to that described by Mizzen and colleagues [25].
The nucleosome preparation was diluted 1:100 in PBS (equiv-
alent to a concentration of 10 µg/ml dsDNA) and coated on
one half of a Nunc Maxisorp plate (the test half). The other half
was coated with PBS alone (the control half). The plates were
washed with PBST and then blocked with 2% casein. After
further washing, samples of antibody were loaded onto the
plate such that each was present in a well on the test half and
a corresponding well on the control half and incubated for 1
hour at 37°C. The plates were washed again with PBST.
Bound antibody was detected by adding goat antihuman IgG
alkaline phosphatase conjugate and incubating for 1 hour at
37°C. Substrate was added and optical density (OD) at 405
nm was read. The true OD for each sample was calculated as
OD in test well – OD in control well
to exclude effects of background nonspecific binding.
Implantation of SCID mice with CHO cells producing 
recombinant IgG
Female Balb/C SCID mice were obtained from Harlan UK
(Bicester, UK) at 6 weeks of age. The mice were all housed in
sterile conditions on vented racks. All procedures were carried
out in accordance with the Animals (Scientific Procedures)
Act 1986. The mice were acclimatised for 1 week before
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pentadecane; Sigma), injected intraperitoneally. Ten days later
the mice were given implants of 1 × 106 CHO cells intraperi-
toneally, in 500 µl of MEMα culture medium.
Two separate experiments were conducted. In the first, five
mice were given implants of CHO-B3 cells, five of CHO-
B3(R27aS) cells, and four of untransfected CHO cells, and
four were given only the initial pristane injection. In the repeat
experiment, five mice were given implants of CHO-B3 cells,
five of CHO-B3(R27aS) cells, and five of CHO cells contain-
ing the empty vector, and three received only the initial pris-
tane injection. In the second experiment, three additional mice
per group were given implants and were killed early, at days 2,
7, and 14 after implantation, to investigate human IgG levels
and any pathological changes that might be transient and not
seen at the end of the experiment.
Throughout the experiment, proteinuria was assessed using
Albustix (Bayer Diagnostics, Newbury, Berkshire, UK). Pro-
teinuria was scored as negative or trace that is negligible; +,
0.3 g/l; ++, 1.0 g/l; +++, 3.0 g/l; and ++++, more than 20 g/
l. The mice were humanely killed either when ascites had
developed to a degree that resulted in a 20% increase in body
weight or when the mice became ill. Their sera, ascites fluid,
and organs were collected for further analysis.
Standard solid-phase ELISAs were used to measure the con-
centration of human IgG antibodies, murine IgM, and murine
IgG antibodies in the sera and/or ascites fluid of the mice at
the end of the experiment. Serum and ascites samples were
titrated from 1:20 to 1:200 000 dilution in PBST for the human
IgG ELISA. Serum samples were diluted to 1:50 and 1:500 in
PBST for the mouse IgG and IgM ELISA.
Haematoxylin and eosin histological stain
Formalin-fixed, paraffin-wax-embedded kidney sections from
the SCID mice were stained with H & E. The sections were
then examined by a histopathologist for morphological evi-
dence of kidney disease.
Staining for human IgG
Formalin-fixed, paraffin-embedded kidney sections were
dewaxed and endogenous peroxidase was blocked using
0.5% H202 in methanol for 10 to 15 min. The sections were
washed in water. The sections were digested in 0.1% pro-
tease XXIV (Sigma) in distilled water adjusted to pH 7.8 with
0.1 M NaOH for 40 min at 37°C in order to expose the antigen
after formalin fixation. The kidney sections were then blocked
with 5% normal swine serum for 10 min. The presence of
human IgG was determined by incubation with rabbit polyclo-
nal antihuman IgG coupled to horseradish peroxidase (Dako
Cytomation, Cambridgeshire, UK) for 1 hour at 37°C before
development with 3,3'-diaminobenzidine.
Enzyme histochemistry staining of neutrophils
The presence of neutrophils as seen in the H & E sections was
confirmed by staining the mouse kidney and liver paraffin-wax
sections for the presence of chloroacetate esterase; the neu-
trophils stained red and the sections were counterstained with
Mayer's haematoxylin.
Electron microscopy
When the mice were killed, a small section of each kidney was
fixed in 2% glutaraldehyde/PBS and these were then embed-
ded and processed for electron microscopy. The electron
microscopic sections were then analysed and photographed
by a specialist histopathologist.
Results
Stable expression of whole IgG molecules in CHO cells
Four stable cell lines were produced, each producing IgG with
the same heavy chain derived from B3, but with different light
chains. These lines were named after the light chain being
secreted, that is, the names were CHO-B3, CHO-B3(R27aS),
CHO-B33, and CHO-BU, as described in Materials and meth-
ods. The sequences of these light chains are shown in Fig. 2.
We chose these four heavy chain/light chain combinations for
expression in CHO cells because previous expression in
COS-7 cells had shown that they possessed a wide range of
ability to bind dsDNA [23]. Thus COS-7 supernatant contain-
ing the combination B3VH/B33VL showed increased binding
to dsDNA compared with the wild-type combination B3VH/
B3VL. Conversely, the combination B3VH/B3(R27aS)VL
showed weaker binding to dsDNA than B3VH/B3VL, and
COS-7 supernatant containing B3VH/BUVLdid not bind
dsDNA at all.
Yields of whole IgG were different for the different constructs.
After two rounds of methotrexate amplification, maximum yield
for CHO-B3 was 130 ng/106 cells per day and maximum yield
for CHO-B3(R27aS) was 250 ng/106 cells per day. Meth-
otrexate amplification led to a total increase in yield of 25-to
30-fold in these lines. For CHO-B33 and CHO-BU, a single
round of amplification at 10-8M methotrexate increased the
yield of IgG to as much as 80-fold in the most productive lines.
Maximum yields were 6,700 ng/106 cells per day for CHO-
B33 and 148 ng/106cells per day for CHO-BU. It is not clear
why the CHO-B33 line should have produced so much more
IgG than the others, but variation in yield depending on the
construct expressed is a common finding both in this expres-
sion system and in others (discussed in [22]). The variation in
yield is not relevant to the results obtained using purified anti-
bodies, which were all tested at the same concentrations (20
to 50 µg/ml). As expected, the control CHOdhfr- cell line,
transfected with empty expression vector (i.e. containing no
heavy chain or light chain variable region cDNA), produced no
detectable IgG.
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Figure 3 shows binding of affinity-purified IgG from the four
heavy/light combinations B3VH/B3VL, B3VH/B3(R27aS)VL,
B3VH/B33VL, and B3VH/BUVL to dsDNA under different con-
ditions. Similar results were obtained in repeated ELISAs.
When the samples are not treated with DNase after being
diluted in SEC, the combination B3VH/B33VL binds dsDNA
but the other three do not (Fig. 3). None of these combinations
binds dsDNA at all when treated with DNase after dilution in
SEC (Fig. 3b). However, when diluted in supernatant from
COS-7 cells that had been electroporated in the absence of
plasmid, three combinations – B3VH/B3VL, B3VH/
B3(R27aS)VL, and B3VH/B33VL – all bind to dsDNA (Fig. 3c),
despite treatment with DNase. The strength of binding
increased in the order B3VH/B3(R27aS)VL<B3VH/B3VL<
B3VH/B33VL. This was the same order seen previously by
expressing these combinations transiently in COS-7 cells. The
combination B3VH/BUVL does not bind dsDNA in ELISA
under any conditions, which also corresponds to results
obtained previously [23].
Binding of affinity-purified antibodies to nucleosomes
Figure 4a shows binding of the four heavy chain/light chain
combinations to nucleosomes in the absence of COS-7 cell
supernatant. The combinations B3VH/B3VL, B3VH/
B3(R27aS)VL, and B3VH/B33VL bind nucleosomes, but
B3VH/BUVL does not. The strength of binding to nucleosomes
was similar for these three combinations. There is a possible
trend to increased strength of binding in the order B3VH/
B3(R27aS)VL<B3VH/B3VL < B3VH/B33VL, as seen in the
anti-dsDNA assay, but the curves are not far enough apart to
Figure 2
Amino acid sequences of expressed Vλ regions compared with their closest germline λ gene, 2a2. The amino acid sequences of B3VL, 
B3(R27aS)VL, B33VL, BUVL, 33.H11VL, and UK-4VL regions are numbered according to the system of Wu and Kabat [26]. Amino acids are indi-
cated by their one-letter code. Dots have been inserted to facilitate the alignment. A dash indicates sequence identity with that of germline gene 2a2. 
The complementarity-determining regions (CDRs) and framework regions (FRs) have been defined according to the system of Wu and Kabat [26]. 
Antigen contact sites, as defined by MacCallum and colleagues [27], are shown by red arrows. L1, L2 and L3 are the first, second and third contact 
regions of the light chain respectively.
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seen at much lower concentrations than binding to dsDNA
(compare Figs 3 and 4).
Since the same three combinations that bound dsDNA on the
addition of COS-7 supernatant (Fig. 3c) also bind nucleo-
somes (Fig. 4a), we carried out experiments to test whether
addition of purified nucleosomes (rather than cell supernatant)
would have the same effect on the binding of these antibodies
to dsDNA. We found that binding of B3VH/B3(R27aS)VL to
dsDNA is reconstituted by adding purified nucleosomes at a
concentration of 10 µg dsDNA/ml (Fig. 4b). This effect was
also seen for this heavy/light combination at a nucleosome
concentration of 2.5 µg dsDNA/ml (though the OD achieved
was lower) but not at nucleosome concentrations of 1.5 µg or
20 µg dsDNA/ml. We were unable to demonstrate
Figure 3
Binding of affinity-purified human IgG molecules to dsDNA. The affinity-
purified human IgG antibodies were tested by ELISA for their binding to 
dsDNA. These experiments were carried out on two separate occa-
sions and representative data are shown. Diluted serum from a patient 
with systemic lupus erythematosus was run on every plate as a positive 
control. The standard deviation (SD) of the standard serum optical den-
sity (OD) value between plates was ± 0.07 at a concentration of 5 IU/
ml. ODs in the control wells containing no antigen were always lower 
than 0.068. (a) The dsDNA binding of the affinity-purified antibodies 
when diluted in sample-enzyme-conjugate (SEC) buffer but not treated 
with DNaseI. Only B3VH/B33VL binds to dsDNA under these condi-
tions. The SDs were as follows: <0.121 OD units for all points on the 
curve B3VH/B33VL and <0.002 OD units for all points on curves B3VH/
B3VL, B3VH/B3(R27aS)VL, and B3VH/BUVL. (b) The dsDNA binding of 
the affinity-purified antibodies when diluted in SEC buffer and treated 
with DNaseI before testing in the ELISA. The DNaseI treatment appears 
to have abolished the binding of the affinity-purified B3VH/B33VL to 
dsDNA. The SD for all points on all four curves was less than 0.002 OD 
units. (c) The dsDNA binding of the affinity-purified antibodies diluted in 
supernatant derived from COS-7 cells and treated with DNaseI before 
testing in the ELISA. The addition of the COS-7 supernatant appears to 
have reinstated the binding of B3VH/B33VL to dsDNA and also allows 
the binding of B3VH/B3VL and B3VH/B3(R27aS)VL to dsDNA. B3VH/
BUVL does not bind to dsDNA. The SDs were as follows: <0.176 OD 
units for all points on the curve B3VH/B33VL, <0.185 OD for all points 
on curve B3VH/B3VL, <0.185 OD for all points on curve B3VH/
B3(R27aS)VL, and <0.01 OD for all points on curve B3VH/BUVL.
Figure 4
Binding of affinity-purified human IgG molecules to nucleosomes. (a) 
Binding of purified DNase-I-treated antibodies to nucleosomes in a 
direct ELISA. The standard deviations were as follows: <0.26 OD for all 
points on the curve B3VH/B33VL, <0.45 OD for all points on the curve 
B3VH/B3VL, <0.33 OD for all points on the curve B3VH/B3(R27aS)VL, 
and <0.01 OD for all points on curve B3VH/BUVL. ODs in the negative 
control wells were all less than 0.07. (b)Binding to dsDNA of purified 
DNase-I-treated antibodies diluted in sample-enzyme-conjugate buffer 
containing nucleosomes at a concentration of 10 µg dsDNA/ml. At this 
concentration of nucleosomes, only B3VH/B3(R27aS)VL binds to 
dsDNA. The same results were obtained when the experiment was 
repeated at a nucleosome concentration of 2.5 µg dsDNA/ml, except 
that the peak OD for the B3VH/B3(R27aS)VL curve was lower. At 
nucleosome concentrations of 1.5 µg or 20 µg dsDNA/ml, none of 
these heavy/light combinations bound dsDNA. The standard deviation 
was <0.18 OD for all points on the curve B3VH/B3(R27aS)VL and 
<0.01 for all the points on all the other curves. ODs in the negative con-
trol wells were all less than 0.068.
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or B3VH/BUVL to dsDNA at any of these four concentrations
of nucleosomes (1.5, 2.5, 10, or 20 µg dsDNA/ml)
Implantation of SCID mice with CHO cells producing 
recombinant IgG
The two lines CHO-B3 and CHO-B3(R27aS) were produced
six months before the other lines. During the period when only
these two lines were available, they were administered to
SCID mice. The major objective of this was to investigate pos-
sible effects of the R27aS mutation on pathogenic potential of
antibody B3. Table 1 shows the results of two separate exper-
iments. The cell lines administered to the mice were the same
in each experiment except that in the second case we used
CHO cells transfected with empty vector as a control rather
than nontransfected CHO cells. The reason for this change
was that we had noted poor growth of nontransfected CHOd-
hfr- cells in the mice in the first experiment and felt that using a
control line that was dhfr+ because it possessed a transfected
plasmid would be a more appropriate control.
With the exception of the nontransfected CHOdhfr- cells in
experiment 1, all the implanted CHO cells grew in all the SCID
mice. When the mice were killed at the end of the experiment,
a few large tumour masses and many small lumps were found
in the peritoneum of the mice, but no differences were
observed between groups. Some of the mice had enlarged
spleens or more peritoneal/ascitic fluid than others, but this
occurred within all groups of mice regardless of the cells
implanted.
The levels of human IgG were assayed in both the sera and
ascites fluid (results not shown, as not all mice had ascites
fluid), and values shown in Table 1 are from blood samples
taken at the end of the experiment. In both experiments 1 and
2, the maximum levels of human IgG were found in the group
given implants of the mutant CHO-B3(R27aS) cells. As
expected, no human IgG was detected in any of the mice given
implants of either nontransfected CHO cells or of CHO cells
transfected with empty vector. The SCID mice were slightly
'leaky' at the end of experiment 2 (at age 3 to 4 months), with
low levels of murine IgM found in the final blood samples of all
the mice. Murine IgG was found in only one mouse, which had
been implanted with CHOdhfr- cells containing the empty
vector.
In both experiments 1 and 2, mice given implants of CHO-B3
had significantly higher levels of proteinuria, up to +++, than
mice given the mutated CHO-B3(R27aS) (P = 0.001 and P =
0.05 respectively). In experiment 2, mice given implants of
CHO-B3 had significantly higher proteinuria than those given
CHOdhfr- containing the empty vector (P = 0.001), although
these mice did have some proteinuria in the range of trace to
+/++. The full results for proteinuria measurement and signifi-
cance tests using ANOVA and Bonferroni correction in both
experiments are shown in Table 1. In both experiments, the
mice that were implanted with CHO-B3 became ill and died
Table 1
Summary of results from two separate experiments implanting CHO cells into SCID mice




Mean proteinuria (estimateda g/l) Mean day of death
Experiment 1
CHO-B3 <16 (3/5), 0 (2/5) ++/+++ to +++ 2.4 20
CHO-B3(R27aS) 260 (2/5), <16 (3/5) + to ++ 0.65 24
Nontransfected CHO only 0 Trace to trace/+ 0.2 34b,c
Pristane only 0 Trace/+ 0.2 34b
Experiment 2
CHO-B3 105 (4/5), NR (1/5) ++ to +++ 2.4 26
CHO-B3(R27aS) 420 (5/5) + to ++/+++ 0.99 39
CHO with empty vector 0 Trace to +/++ 0.38 48
Pristane only 0 Trace/+ 0.2 56b
aProteinuria was assessed using Albustix, which give a semiquantitative measure based on colour change. Based on values provided with the 
Albustix, in order to calculate the estimated proteinuria in g/l we assumed that trace = 0.1 g/l, trace/+ = 0.2 g/l, +/++ = 0.65 g/l, and ++/+++ = 
2.0 g/l. The proteinuria data in both experiments were found to be normally distributed using the Kolmogorov–Smirnov test and compared using a 
one-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparison test. In experiment 1, the ANOVA showed that there was a 
significant difference between the mean proteinuria values of all the groups (P < 0.0001). The Bonferroni post test indicated that there was a 
significant difference between mice implanted with CHO-B3 and CHO-B3(R27aS) (P < 0.001), nontransfected CHOdhfr- cells (P < 0.001), and 
pristane only (P < 0.001). In experiment 2, the ANOVA showed that there was a significant difference between the mean proteinuria values of all the 
groups (P < 0.0003). The Bonferroni post test indicated that there was a significant difference between mice implanted with CHO-B3 and CHO-
B3(R27aS) (P < 0.05), CHO cells containing the empty vector (P < 0.001), and pristane only (P < 0.01). bMice still healthy at the end of the 
experiment. cThese cells did not survive/grow in the mice. CHO, Chinese hamster ovary; NR, not recorded; SCID, severe combined 
immunodeficiency.
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B3(R27aS) or the control groups (Table 1 and Fig. 5). Figure
5 is a set of Kaplan–Meier curves showing a significant differ-
ence in survival between the groups (P = 0.0001 by log-rank
test). It is particularly striking that the life expectancy of mice
implanted with CHO cells containing empty vector was almost
twice that of mice implanted with CHO-B3.
Despite the significant levels of proteinuria that we observed
in the mice implanted with CHO-B3, H & E staining of kidney
sections showed no evidence of 'lupus-like' morphology in any
of the groups of mice. Staining with rabbit antihuman IgG cou-
pled to horseradish peroxidase developed with 3,3'-diami-
nobenzidine also failed to detect any deposition of human
antibody in kidneys from any of the mice. There was evidence
of non-SLE-related pathology, namely, neutrophil infiltration of
kidney glomeruli and of the liver, and liver necrosis. Such
pathology occurred in all the groups of mice implanted with
either CHO-B3, CHO-B3(R27aS), or CHOdhfr- containing
empty vector and was most marked in the CHOdhfr- and
empty-vector groups. This may have been due to the fact that
these mice were killed later, because they were less ill. Mice
killed at day 2, 7, or 14 showed consistently less pathology,
with immature neutrophil infiltration, compared to mice
implanted with the same cells but kept alive till the end of the
experiment. Electron microscopy revealed very limited mor-
phological changes: mesangial cell interposition, splitting of
the basement membrane, and some microvillus transforma-
tion. However, these changes were present in all groups
(CHO-B3, CHO-B3(R27aS), and CHOdhfr- containing empty
vector). In all groups, the foot processes were normal, and
there was no thickening of the basement membrane and no
evidence of immune deposits.
Discussion
We have successfully developed a stable expression system
to produce recombinant human anti-DNA antibodies. This
methodology allows the investigation, both in vitro and in vivo,
of the functional effects of sequence alterations in such anti-
bodies. Even after methotrexate amplification, the expression
of these antibodies by the CHO cells is low, in comparison
with the amounts produced by hybridoma cells, but use of a
commercial system allowed us to obtain milligram yields of
purified recombinant antibody.
One interpretation of the results obtained from ELISA tests
using the purified antibodies is that the wild-type antibody,
B3VH/B3VL, shows binding to dsDNA strong enough to be
detected by ELISA only when the antibody is complexed with
some component present in supernatant of electroporated
COS-7 cells. This complex dissociates when the antibody is
affinity-purified, so binding is lost. When supernatant is added,
the ability to bind dsDNA is restored. The same is true of
B3VH/B3(R27aS)VL, but binding is weaker. The combination
B3VH/B33VL binds more strongly to this component from
supernatant, so that the complex does not dissociate fully dur-
ing affinity purification. Thus, affinity-purified B3VH/B33VL
diluted in SEC buffer binds dsDNA. That this binding is lost on
treatment with DNase suggests that the component com-
plexed with B3VH/B33VL is a bridging nucleoprotein of some
kind, which is essential for binding of this antibody to dsDNA.
If the complexed component were dsDNA alone, then
digestion with DNaseI would increase binding to dsDNA on
the plate rather than decreasing it.
This interpretation of results obtained using human antibodies
is very similar to the arguments of Kramers and colleagues
[10] and Guth and colleagues [12], following their experi-
ments using murine antibodies. Kramers and colleagues
showed that purification of monoclonal murine antibodies from
hybridoma supernatant using DNase and high-salt conditions
before loading on a protein A column was necessary to pro-
duce noncomplexed antibodies. These antibodies would bind
to nucleosomes but not dsDNA, whereas if high salt and
DNase were not used, the antibodies remained complexed to
nucleosomes and would bind dsDNA. Guth and colleagues
obtained similar results using antibodies 3H9 and SN5-18,
derived from two different autoimmune mouse strains. Both
antibodies bound chromatin, but not histones or dsDNA, when
highly purified, whereas unpurified hybridoma supernatant or
standard protein G preparation of 3H9 did bind dsDNA.
Supernatant or protein G preparation of SN5-18 bound his-
tones. When cell culture supernatant from SP2/0 cells was
added to highly purified 3H9, ability to bind dsDNA was
restored. The conclusion was that incomplete purification of
such antibodies can lead them to appear to bind dsDNA,
whereas the true antigen is a complex of dsDNA, histone 2A,
and histone 2B.
Figure 5
Percentage survival over time of mice given implants of CHO cells pro-ducing recombinant human IgG
ducing recombinant human IgG. This Kaplan–Meier plot shows the per-
centage of mice in each group that were still alive at each time point in 
the second experiment. The curves are significantly different by the log-
rank test (P = 0.0001). There was reduced survival of mice in the 
groups that were given implants of Chinese hamster ovary (CHO) cells 
producing B3 and B3(R27aS), as compared with those mice in groups 
that were given CHO cells containing the empty vector or that were 
only primed with pristane. The mice were killed when they became ill; 
there was no evidence of ascites growth in any of these mice.
Arthritis Research & Therapy    Vol 7 No 5    Mason et al.
R980It is important to note, however, that there is another possible
interpretation of our results. DNase treatment may well alter
DNA in solution in such a way that it acts as a competitive
inhibitor of binding of antibody to dsDNA on the plate. When
DNaseI is added to an incompletely dissociated complex of
dsDNA with B3VH/B33VL, it may generate small fragments of
DNA (perhaps ssDNA). These fragments may remain associ-
ated with the antibody or may gain access to the combining
site and act as efficient competitors of binding to dsDNA. The
supernatants of the dying COS-7 cells could release other
nucleases that purge the combining site more effectively, thus
renewing binding. However, this theory does not explain why
B3VH/B3VL and B3VH/B3(R27aS)VL do not bind dsDNA in
the absence of COS-7 supernatants even in the absence of
DNaseI, but will bind it when these supernatants are added.
During electroporation of COS-7 cells, approximately 80% of
the cells are believed to die. The supernatant of those cells is
therefore rich in debris from dying cells. Nucleosomes are part
of this material and contain DNA. Nucleosomes might there-
fore be the cofactor from the COS-7 supernatant that binds
the expressed antibodies and enables them to bind dsDNA in
ELISA. If this were true, one would expect the purified DNase-
treated antibodies to be able to bind nucleosomes. The results
shown in Fig. 4a confirm this. The combinations B3VH/B3VL,
B3VH/B3(R27aS)VL, and B3VH/B33VL bind nucleosomes,
without requiring the addition of cell supernatant. Guth and
colleagues [12] showed that arginine-to-serine mutations in
VHCDR3 of SN5-18 ablate binding to chromatin. The single
arginine-to-serine mutation in B3(R27aS)VL did not ablate
binding to nucleosomes but may have reduced it slightly.
Replacement of CDR2 and CDR3 of B3VL by those of 33H11
or UK-4 gave different effects on binding to nucleosomes,
even though these three light chains are derived from the same
germline gene and differ only at positions of somatic mutations
(see Fig. 2). In particular, the combination B3VH/BUVL does
not bind nucleosomes at all.
It was puzzling that addition of purified nucleosomes could
reconstitute the binding of B3VH/B3(R27aS)VL to dsDNA but
not that of combinations B3VH/B3VL or B3VH/B33VL, which
bind nucleosomes as well as B3VH/B3(R27aS)VL in direct
ELISA. It is clear from the experiments with B3VH/
B3(R27aS)VL that the concentration of nucleosomes is critical
to their ability to act as a cofactor in the binding of this anti-
body to dsDNA. This may well also be true of the other two
combinations. Perhaps some non-nucleosome component of
the supernatant, such as a nuclease that removes a competi-
tive inhibitor from the binding site, is playing a role in promoting
the binding of B3VH/B3VL and B3VH/B33VL to dsDNA. Alter-
natively, in order to bind dsDNA perhaps these two heavy/light
combinations require the presence of some nucleoprotein
cofactor that is not found in our nucleosome preparation.
We postulate that the arginines at positions 27a and 92 of
B33VL both interact with the dsDNA component of the nucle-
osome, as predicted by the previous computer model [23], but
it seems likely that other sequence motifs on the antibody
interact with the histone component to enhance antibody/
nucleosome binding. These motifs are not likely to be arginine
residues, as histones are positively charged.
A number of research groups have previously described stable
expression of murine anti-DNA antibodies from cloned cDNA
[19,20,28]. In most cases, expression was achieved using
heavy chain-loss variants, which are hybridoma cells that have
lost the ability to secrete heavy chains. By transfecting such
variants with expression vectors encoding various different
heavy chains, Radic and colleagues [19], Katz and colleagues
[20], and Pewzner-Jung and colleagues [28] were all able to
demonstrate that altering the numbers of arginines in CDRs of
the heavy chains altered the ability of murine monoclonal anti-
bodies to bind DNA. Of these research groups, only Katz and
colleagues [20] went on to test the ability of the altered anti-
bodies to cause pathogenic changes in mice. They produced
antibodies based on the murine monoclonal anti-DNA anti-
body R4A. All these antibodies had the light chain of R4A, but
the heavy chains were variants of the R4A VH sequence. They
found that the antibody with strongest binding to dsDNA did
not have more CDR arginines than wild-type R4A VH. This anti-
body actually showed less glomerular binding but more tubular
binding to mouse kidneys in vivo than the wild-type R4A.
Only one research group has previously reported stable
expression of whole human anti-dsDNA molecules (as
opposed to Fab or single chain Fv fragments) in vitro. Li and
colleagues [21] expressed the variable region sequences of
the human IgA anti-DNA antibody 412.67 in F3B6 human/
mouse heteromyeloma cells. The products were whole IgG
molecules, since the expression vectors contained γ, rather
than α, constant regions. In an elegant series of experiments,
this group showed that reversion of two arginines in 412.67
VH CDR3 totally removed the ability to bind ssDNA or dsDNA.
All somatic mutations outside VH CDR3 in either VH or VL of
this antibody, however, could be reverted with no effect on
DNA binding. No data were presented regarding the effect of
these sequence changes on pathogenicity, and it is not known
whether the original IgA antibody 412.67 is pathogenic in
mice.
The stable expression of antibody B3 described here, there-
fore, is only the second report of stable expression of a whole
human anti-dsDNA antibody in vitro. Expression of B3 repre-
sents the first opportunity to allow testing of the effects of
sequence alterations on the pathogenicity of a human anti-
body already known to cause proteinuria in SCID mice.
The major finding from the experiments in the SCID mice was
the marked and reproducible differences between outcomes
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CHO-B3 died earlier and developed more proteinuria than
those given CHO-B3(R27aS). Both these groups of mice
developed more proteinuria and died earlier than mice in the
control groups, given implants of CHO cells that did not pro-
duce IgG.
The difference in outcomes between the CHO-B3 and CHO-
B3(R27aS) groups is not likely to be due to differences in
tumour load or antibody expression between these groups.
Serum human IgG levels were higher in the CHO-B3(R27aS)
group (Table 1). These mice were therefore exposed to more
human IgG but still lived longer than the CHO-B3 group. This
suggests that the earlier deaths of mice in the CHO-B3 group
were due either to the difference in the antibody sequence or
to some direct effect of the cell line that is not so evident with
the CHO-B3(R27aS) line.
It seems unlikely that the effects seen were simply due to the
presence of CHO cells in SCID mice, since we used two sets
of nonsecreting CHO lines as control groups. Although non-
transfected CHOdhfr- cells used in experiment 1 did not grow
well in vivo, this did not apply to the cells transfected with
empty vector in experiment 2. Although some of these mice
developed proteinuria, this occurred much later, and to a
lesser degree, than in the mice who received CHO-B3 or
CHO-B3(R27aS). We note that intraperitoneal introduction of
pristane causes inflammation, which could lead to apoptosis,
necrosis, and release of nucleosomes. Since the degree of
inflammation will be different in different mice, this could lead
to variability in the results within groups of animals exposed to
the same antibody.
The main reason to question whether the expressed antibod-
ies actually caused the proteinuria and early death in the CHO-
B3 and CHO-B3(R27aS) groups is the lack of evidence of
deposition of the antibodies in the kidneys of the mice. One
reason for this may be that the level of human IgG measured
in the sera was very low in both the CHO-B3 and CHO-
B3(R27aS) groups. In comparison, the serum levels of human
IgG that were previously observed in our experiments implant-
ing human anti-DNA hybridoma cells (including hybridoma
secreting B3) into SCID mice were 1,000 times as high [8,9].
However, the level of antibody production by the transfected
CHO cells in vivo is consistent with the level of their in vitro
production (shown in Table 1), which is also much lower than
that seen in hybridoma cells in vitro. Secretion of human IgG
does not appear to be transient in this system, since additional
mice killed earlier, at either 2, 7, or 14 days after implantation,
had lower serum human IgG levels than those killed later (data
not shown).
It is intriguing that, despite these low levels of circulating
human IgG, the level of proteinuria observed here with con-
centrations of human recombinant B3 amounting to nano-
grams per millilitre, is the same as that observed in SCID mice
implanted with hybridoma cells producing B3 [8]. This finding
was reproducible and occurred even though we could not
demonstrate deposition of the antibody in either the kidney or
nuclei of other tissues.
Is it feasible that low levels of human anti-DNA antibodies, as
secreted by the CHO cells in our experiments, are sufficient to
cause the clinical outcomes of proteinuria and early death but
insufficient to cause pathology observable by histological
change? It appears that despite using SCID mice, the system
was complicated by pathology resulting from an innate
immune response, in the form of neutrophil infiltration, directed
against the CHO cells. This infiltration was seen in all groups
of mice implanted with CHO cells, including the nonsecreting
controls. It is possible that this response may have led to up-
regulation of molecules such as α-actinin, which have been
postulated to be renal targets for pathogenic anti-DNA
antibodies [29,30]. This could make the kidneys of these mice
more susceptible to the effects of small amounts of such
antibodies.
These results suggest that, although these expressed antibod-
ies may exert pathogenic effects in mice, the limitations of our
system using CHO cells in SCID mice do not allow us to be
confident about this. Alternative approaches include intrave-
nous injection of purified antibody [31], but this would only
enable demonstration of renal deposition and not pathogenic-
ity, unless repeated injections were given over a period of
several days to weeks. This would require far greater quanti-
ties of antibodies than we have at present. One might also
attempt to modify the expression vectors such that they could
be introduced into embryos to create mice transgenic for
human B3 VH and VL. However, previous experiments with
murine anti-dsDNA transgenes raise the possibility that cells
expressing such transgenes might be removed by deletion or
receptor editing [32]. Lastly, one might apply purified antibod-
ies to cultured renal cell lines, such as the temperature-sensi-
tive podocyte line described by Saleem and colleagues [33] or
mesangial cell lines used by Putterman and colleagues [30].
Conclusion
In conclusion, we have established a system for the stable
expression and purification of human IgG autoantibodies in
CHO cells. This system was used to show that the antibody
B3 is probably an antinucleosome antibody, which does not
bind dsDNA after purification. Changing the sequence of B3
light chain alters binding to nucleosomes. Further experiments
are necessary to investigate the effects of these changes on
pathogenicity of the antibodies.
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